Stock Sale, Buyback News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, res...

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM   1. Details of the per...

SAN FRANCISCO--(BUSINESS WIRE)--Wells Fargo & Company (NYSE: WFC) (“Wells Fargo”) today announced that it will redeem all of its Floating Rate Junior Subordinated Deferrable Interest Debentures due January 15, 2027 (CUSIP No. 949746TG6*) (the “Debentures”) on January 15, 2026 (the “Optional Prepayment Date”). The optional prepayment price will be equal to 100% of the principal amount of the Debentures plus accrued and unpaid interest to, but excluding, the Optional Prepayment Date. Upon the...

FORT MILL, S.C.--(BUSINESS WIRE)--Shoe Carnival, Inc. (Nasdaq: SCVL) (the “Company”), a leading retailer of footwear and accessories for the family, announced today that its Board of Directors approved the payment of a quarterly cash dividend of $0.15 per share to be paid on January 26, 2026, to shareholders of record as of the close of business on January 12, 2026. Additionally, its Board of Directors authorized a new share repurchase program for up to $50 million of its outstanding common sto...

LONDON & DENVER & JOHANNESBURG--(BUSINESS WIRE)--AngloGold Ashanti plc (the “Company”) (NYSE: AU; JSE: ANG) announces that an Executive Director, Alberto Calderon, has dealt in securities of the Company. Following the sale, Mr. Calderon continues to hold 338,849 shares and share incentive awards, and another 253,965 shares under the Performance Share Plan which have yet to vest. Name of Executive Director Alberto Calderon Name of Company AngloGold Ashanti plc Date of transaction 10 December 202...

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the pricing of an upsized underwritten public offering of 7,346,938 shares of its Class A common stock at a public offering price of $12.25 per share. In addition, Contineum has granted the underwriters a 30-day optio...

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--PennyMac Mortgage Investment Trust (NYSE: PMT) (“PMT” or the “Company”) today announced that its indirect wholly-owned subsidiary, PennyMac Corp. (“PMC”), has priced an offering of $75 million aggregate principal amount of its 8.500% Exchangeable Senior Notes due 2029 (the “Notes”) to certain investors in a direct placement registered under the Securities Act of 1933, as amended. The Notes will be issued as a reopening of, and will be part of the same...

THE WOODLANDS, Texas--(BUSINESS WIRE)--Excelerate Energy, Inc. (the “Company” or “Excelerate”) (NYSE: EE) announced today that its Board of Directors (the “Board”) approved a new share repurchase authorization, pursuant to which the Company may purchase up to $75 million of its Class A common shares. Dana Armstrong, Chief Financial Officer, said, “Our approach to share repurchases reflects a commitment to enhancing shareholder returns while maintaining flexibility for growth investments and div...

RICHMOND, Va.--(BUSINESS WIRE)--Kinsale Capital Group Authorizes New $250 Million Share Repurchase Program...

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the commencement of an underwritten public offering of $75.0 million of shares of its Class A common stock. In addition, Contineum intends to grant the underwriters a 30-day option to purchase up to an additional $11....